Myasthenia gravis is an autoimmune disorder affecting neuromuscular junction. Corticosteroid and
other immunosuppressive agents are used for the treatment of myasthenia gravis. Tacrolimus may
also have a potential role in long-term supression of the immune system. There are limited but promising
data to suggest beneficial effects of tacrolimus to control myasthenia gravis and to reduce corticosteroid
burden. To date, the largest randomised controlled trial could not demonstrate significant
differences in their primary endpoint. Therefore, additional well designed and high quality studies
are necessary to determine the effects of tacrolimus on myasthenia gravis.